GlassScriptPhysician profile
Eric O Shreder
NPI 1982712519
$5,923.48
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,704 · 2020: $1,761 · 2021: $1,729 · 2022: $652 · 2023: $64.51 · 2024: $13.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $660.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $547.66 | 2019-2022 | |
| Glaxosmithkline, LLC. | $473.25 | 2019-2022 | |
| Abbvie INC. | $378.18 | 2019-2022 | |
| Pfizer INC. | $370.17 | 2019-2022 | |
| Amgen INC. | $352.74 | 2019-2022 | |
| Lilly USA, LLC | $348.23 | 2019-2022 | |
| Allergan, INC. | $277.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.91 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $156.55 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.38 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $132.84 | 2019-2021 | |
| Galderma Laboratories, L.P. | $130.55 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $124.17 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shreder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.